EXPAREL市場：市場規模、予測、新たな洞察-2032年

EXPAREL（ブピバカインリポソーム注射用懸濁液）は、成人の術後局所鎮痛を目的とした単回浸潤、および術後局所鎮痛を目的とした鎖骨間腕神経叢神経ブロックを適応としています。その他の神経ブロックにおける安全性および有効性は確立していません。本製品は、ブピバカインとDepoFoamを組み合わせたもので、薬剤を必要な期間にわたって送達する実績のある製品送達技術です。EXPARELは、手術前後で使用可能な多包膜リポソーム局所麻酔薬です。DepoFoamプラットフォームを利用することにより、EXPARELの単回投与でブピバカインを長期にわたって投与し、累積疼痛スコアの有意な減少をもたらし、オピオイド消費量を最大78％減少させます。

今後数年間で、世界中の広範な調査と医療費の増加により、術後痛の市場シナリオは変化します。各社は、病態を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、EXPARELの優位性に影響を与える可能性のある機会を模索しています。術後疼痛を対象とした他の新興製品もEXPARELと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるEXPAREL市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 術後疼痛に関するEXPARELの概要

• 製品詳細
• 臨床開発
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 EXPAREL市場評価

• 術後疼痛に対するEXPARELの市場展望
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: EXPAREL, Clinical Trial Description, 2023
• Table 2: EXPAREL, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: EXPAREL Market Size in the 7MM, in USD million (2019-2032)
• Table 6: EXPAREL Market Size in the US, in USD million (2019-2032)
• Table 7: EXPAREL Market Size in Germany, in USD million (2019-2032)
• Table 8: EXPAREL Market Size in France, in USD million (2019-2032)
• Table 9: EXPAREL Market Size in Italy, in USD million (2019-2032)
• Table 10: EXPAREL Market Size in Spain, in USD million (2019-2032)
• Table 11: EXPAREL Market Size in the UK, in USD million (2019-2032)
• Table 12: EXPAREL Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: EXPAREL Market Size in the 7MM, USD million (2019-2032)
• Figure 2: EXPAREL Market Size in the United States, USD million (2019-2032)
• Figure 3: EXPAREL Market Size in Germany, USD million (2019-2032)
• Figure 4: EXPAREL Market Size in France, USD million (2019-2032)
• Figure 5: EXPAREL Market Size in Italy, USD million (2019-2032)
• Figure 6: EXPAREL Market Size in Spain, USD million (2019-2032)
• Figure 7: EXPAREL Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: EXPAREL Market Size in Japan, USD million (2019-2032)

"EXPAREL Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about EXPAREL for Postoperative pain in the seven major markets. A detailed picture of the EXPAREL for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the EXPAREL for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EXPAREL market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired period. EXPAREL represents the multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78% decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the EXPAREL description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on EXPAREL regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EXPAREL research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around EXPAREL.
• The report contains forecasted sales of EXPAREL for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for EXPAREL in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EXPAREL Analytical Perspective by DelveInsight

• In-depth EXPAREL Market Assessment

This report provides a detailed market assessment of EXPAREL for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• EXPAREL Clinical Assessment

The report provides the clinical trials information of EXPAREL for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EXPAREL dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to EXPAREL and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EXPAREL in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of EXPAREL from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EXPAREL in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of EXPAREL?
• What is the clinical trial status of the study related to EXPAREL in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EXPAREL development?
• What are the key designations that have been granted to EXPAREL for Postoperative pain?
• What is the forecasted market scenario of EXPAREL for Postoperative pain?
• What are the forecasted sales of EXPAREL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to EXPAREL for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. EXPAREL Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. EXPAREL Market Assessment

• 5.1. Market Outlook of EXPAREL in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of EXPAREL in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of EXPAREL in the United States for Postoperative pain
  • 5.3.2. Market Size of EXPAREL in Germany for Postoperative pain
  • 5.3.3. Market Size of EXPAREL in France for Postoperative pain
  • 5.3.4. Market Size of EXPAREL in Italy for Postoperative pain
  • 5.3.5. Market Size of EXPAREL in Spain for Postoperative pain
  • 5.3.6. Market Size of EXPAREL in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of EXPAREL in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options